THE MCMANUS GROUP for GILEAD SCIENCES, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R.5378 - Lower Costs, More Transparency Act Issues related to Part D delinking of PBMs, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.5378 - Lower Costs, More Transparency Act Issues related to commercial delinking of PBMs - H.R.6283/S.1542 - DRUG Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.